Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
Standard
Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. / Escherich, Gabriele; Zimmermann, Martin; Janka-Schaub, Gritta; COALL study group.
in: PEDIATR BLOOD CANCER, Jahrgang 60, Nr. 2, 2, 2013, S. 254-257.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
AU - Escherich, Gabriele
AU - Zimmermann, Martin
AU - Janka-Schaub, Gritta
AU - COALL study group
PY - 2013
Y1 - 2013
N2 - The anthracyclines daunorubicin (DNR) and doxorubicin (DOX) are among the most important drugs in the treatment of childhood acute lymphoblastic leukemia, however there are conflicting in vitro data about the comparative efficacy and equivalent doses of both anthracyclines. To address the question of in vivo efficacy of both anthracyclines, patients enrolled in the CoALL 07-03 trial were randomized to receive one single dose of either doxorubicin 30?mg/m(2) , daunorubicin 30?mg/m(2) , or daunorubicin 40?mg/m(2) upfront induction therapy.
AB - The anthracyclines daunorubicin (DNR) and doxorubicin (DOX) are among the most important drugs in the treatment of childhood acute lymphoblastic leukemia, however there are conflicting in vitro data about the comparative efficacy and equivalent doses of both anthracyclines. To address the question of in vivo efficacy of both anthracyclines, patients enrolled in the CoALL 07-03 trial were randomized to receive one single dose of either doxorubicin 30?mg/m(2) , daunorubicin 30?mg/m(2) , or daunorubicin 40?mg/m(2) upfront induction therapy.
KW - Humans
KW - Male
KW - Female
KW - Adolescent
KW - Child
KW - Disease-Free Survival
KW - Child, Preschool
KW - Infant
KW - Kaplan-Meier Estimate
KW - Antineoplastic Agents/therapeutic use
KW - Daunorubicin/therapeutic use
KW - Doxorubicin/therapeutic use
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/mortality
KW - Humans
KW - Male
KW - Female
KW - Adolescent
KW - Child
KW - Disease-Free Survival
KW - Child, Preschool
KW - Infant
KW - Kaplan-Meier Estimate
KW - Antineoplastic Agents/therapeutic use
KW - Daunorubicin/therapeutic use
KW - Doxorubicin/therapeutic use
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/mortality
M3 - SCORING: Journal article
VL - 60
SP - 254
EP - 257
JO - PEDIATR BLOOD CANCER
JF - PEDIATR BLOOD CANCER
SN - 1545-5009
IS - 2
M1 - 2
ER -